1.
Pediatr Infect Dis J
; 36(11): e283-e285, 2017 Nov.
Artículo
en Inglés
| MEDLINE
| ID: mdl-28719496
RESUMEN
In an open-label study in India, 200 healthy participants 6-17 years of age received 13-valent pneumococcal conjugate vaccine (PCV13). PCV13 elicited robust functional antibody immune responses. No adverse events were reported by caregivers at the 1-month follow-up visit. The immunogenicity results together with the known favorable risk-benefit profile of PCV13 support extension of the indication to this age group in India.